GERN
Now that yesterday's PR confirms what we thought may have been a typo, the efficacy of GERN's vaccine seems strong ?
What I mean is, the mean PSADT of 100 months looks remarkable ? Compare with Provenge in the recent phase II trial (P-16 or P-11 ?) results ?
I know comparing phase IIs doesn't mean much, but you can't avoid the numbers .... ?
"....on the biotech battle-field, you need some élan...."